Study wrapper · #286
The glycyl-l-histidyl-l-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6.
Editor's note
This is a mechanistically focused animal-and-cell study of GHK-Cu in silicosis - the incurable, progressive lung scarring caused by chronic crystalline-silica exposure, for which no specific drug exists. That unmet need makes any lead noteworthy, but the evidence stage must be kept clear. In a mouse silicosis model and in RAW264.7 macrophages, researchers report that GHK-Cu reduced lung inflammation and fibrosis, and they identify peroxiredoxin 6 (PRDX6) as a molecular target the peptide binds, with the benefit linked to dampened silica-induced oxidative stress in alveolar macrophages. Notably, they report this occurred 'without significant systemic toxicity' in the model. The target-identification work adds mechanistic credibility beyond a simple observed effect. But this is an induced disease in mice plus a macrophage cell line - a mechanistic signal, not clinical proof - and there are no human data for GHK-Cu in lung disease. These are preclinical findings; human data would be needed before any clinical conclusions could be drawn. A promising but early mechanistic lead.
Plain-language abstract
Silicosis is a serious, progressive lung disease caused by long-term inhalation of crystalline silica dust, common among certain workers, and there is currently no specific medicine for it. GHK, a copper-binding peptide found naturally in human blood and urine, has antioxidant effects, and this study tested whether its copper form, GHK-Cu, could help. Researchers created a silicosis model in mice and also studied a type of lung immune cell (alveolar macrophages) using a cell line. GHK-Cu reduced lung inflammation and scarring (fibrosis) in the mice, and it did so without causing significant whole-body toxicity in the model. The researchers identified a specific protein, peroxiredoxin 6 (PRDX6), that GHK-Cu binds to, and found that the peptide worked partly by reducing the silica-driven oxidative stress in the lung immune cells. The authors suggest GHK-Cu could be a potential drug candidate for silicosis by protecting these immune cells and slowing the progression of lung inflammation and scarring. This was research in mice and cells; human data would be needed before drawing any conclusions about treating people.